Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, commercial and real world insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share diverse insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health is powered by an authentic, inclusive and high-performance culture that cares for colleagues, customers, patients, communities and the environment.
Syneos Health の市場拡大を追跡しています
新しいマーケティング・PRのアクティビティ — 17 件の新規シグナルが出現しました。
Syneos Health の海外展開を競合と比較
Syneos Health自社バーは比較対象企業間の相対的な規模を示します。
列5| 企業 | 市場 | 新規市場 | モメンタム | アクティビティ | 拡大スコア |
|---|---|---|---|---|---|
 Syneos Health自社 | 0 | 0 | — | 0 | 0 |
Bus Proc & Perf Analyst
求人を見るBuenos Aires, Buenos Aires Province, Argentina · 一昨日
L&D Trainer
求人を見るBuenos Aires, Buenos Aires Province, Argentina · 一昨日
Clinical Support Specialist
求人を見るBuenos Aires, Buenos Aires Province, Argentina · 一昨日
Incretins. CKM therapies. Combination treatments. Cardiometabolic innovation is advancing rapidly—but complexity is growing just as fast.Discover how our cross-therapeutic model helps sponsors accelerate development in cardiovascular, metabolic and renal programs with greater clarity and speed to market. ...
終了
The future of cardiometabolic drug development depends on seeing the full picture.Risk doesn't develop in silos and neither should our development strategies.As we head into ADA 2026, I share perspectives on why approaching cardiometabolic disease as an interconnected continuum may help reshape how we think about trial design, risk management and long-term patient outcomes.Read more: Rethinking Risk, Improving Outcomes in Cardiometabolic Drug Development https://lnkd.in/ePUtrRs3If you will be at ...
終了
Two incredible days of conversations recorded live from the Syneos Health Early Signals podcast booth on the ASCO conference floor 🎙️Over the past 48 hours, I’ve had the opportunity to sit down with leaders across oncology, precision medicine, cell therapy and drug development to discuss the innovations, challenges and breakthroughs shaping what comes next for patients.These are just some of the conversations from the last two days at ASCO, and I’m incredibly grateful to Diana Chen, Nick Glover ...
終了Veeva SystemsのVault EDCが1000以上の試験を支援し、上位20社のバイオ医薬品企業のうち8社が標準化、臨床データ管理の効率を向上。
Telix Pharmaceuticalsは2026年5月11日付でDavid Gillを社外取締役に任命し、将来的に会長就任を予定。Gillは35年以上のライフサイエンス経験を持つ。
CrossjectはSyneos Healthと提携し、無針自動注射器技術を使用した緊急てんかん治療薬ZEPIZUREの米国での商業発売を行います。
認証済みメールと直通電話を解放
無料 · カード不要
Syneos Health の事業、市場、成長シグナルに関する簡潔な回答。
© 2026 Pubrio. 無断転載を禁じます。
